Launch of "Gasmotin", a gastroprokinetic drug in Japan
Dainippon Pharmaceutical Co., Ltd. launched Gasmotin ( mosapride citrate ), a gastroprokinetic drug that improves symptoms associated with chronic gastritis, on October 1, 1998.
It is the world's first gastroprokinetic drug, specifically acting to serotonin 5-HT4 receptor. The product stimulates serotonin 5-HT4 receptor in the gastrointestinal nerve plexus, which increases the release of acetylcholine, resulting in enhancement of gastrointestinal motility and gastric emptying.
Unlike most of the similar products, Gasmotin does not cause extrapyramidal symptoms nor endocrine disorders because it does not show dopamine D2 receptor antagonist activity. In addition, it does not cause the venticular arrhythmia which some of the similar products cause.
While most of the similar drugs must be taken before meals, Gasmotin can be taken either before or after meals because no effect by meal is observed.
Dainippon regards it as a global strategic product. It was licensed out to Astra AB for development and marketing for the US and Europe, where early Phase II studies are underway.
Dainabot will co-promote Gasmotin.